UniSuper Management’s United Therapeutics UTHR Stock Holding History

UniSuper Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$508K	Buy	938 +238	+34%	+$134K	﹤0.01%	579
2026 Q1	$415K	Hold	700	–	–	﹤0.01%	597
2025 Q4	$341K	Hold	700	–	–	﹤0.01%	617
2025 Q3	$293K	Hold	700	–	–	﹤0.01%	645
2025 Q2	$201K	Sell	700 -100	-13%	-$29.9K	﹤0.01%	682
2025 Q1	$247K	Hold	800	–	–	﹤0.01%	675
2024 Q4	$282K	Sell	800 -13,826	-95%	-$5.08M	﹤0.01%	654
2024 Q3	$5.24M	Buy	14,626 +13,526	+1,230%	+$4.57M	0.04%	225
2024 Q2	$350K	Buy	1,100 +400	+57%	+$106K	﹤0.01%	877
2024 Q1	$161K	Buy	700 +400	+133%	+$90.3K	﹤0.01%	949
2023 Q4	$66K	Hold	300	–	–	﹤0.01%	708
2023 Q3	$67.8K	Hold	300	–	–	﹤0.01%	664
2023 Q2	$66.2K	Buy	+300	New	+$66.5K	﹤0.01%	667

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

UniSuper Management's UTHR Position: Q2 2026 in Review

UniSuper Management increased its United Therapeutics (UTHR) stake by 34% in Q2 2026, buying an estimated $134K and bringing the position to 938 shares worth $508K. The position accounts for ﹤0.01% of the portfolio, ranked #579.

UniSuper Management first reported a position in UTHR in Q2 2023 and has held it in 13 quarters since. The position peaked at $5.24M in Q3 2024. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

UniSuper Management held 938 shares of United Therapeutics worth $508K as of Q2 2026.
UniSuper Management bought 238 United Therapeutics shares in Q2 2026, an estimated $134K.
United Therapeutics made up ﹤0.01% of UniSuper Management's portfolio in Q2 2026, its #579 holding.
UniSuper Management first reported a position in United Therapeutics in Q2 2023 and has held it in 13 quarters since.
UniSuper Management's United Therapeutics position peaked at $5.24M in Q3 2024.
878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on UniSuper Management's 13F filing for Q2 2026, filed 14 Aug 2026.